東華大學圖書館 |

Pharmaceutical statistics = MBSW 39, Muncie, Indiana, USA, May 16-18, 2016 /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pharmaceutical statistics/ edited by Ray Liu, Yi Tsong.
其他題名:	MBSW 39, Muncie, Indiana, USA, May 16-18, 2016 /
其他作者:	Liu, Ray.
團體作者:	Midwest Biopharmaceutical Statistics Workshop
出版者:	Cham :Springer International Publishing : : 2019.,
面頁冊數:	xi, 337 p. :ill., digital ;24 cm.
內容註:	Part I: Specification and Sampling Acceptance Tests -- Statistical Considerations in Setting Quality Specification Limits Using Quality Data -- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes -- Part II: Analytical Biosimilar and Process Validation -- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment -- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study -- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment -- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules -- Part III: Continuous Process -- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach -- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle -- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach -- Part IV: Clinical Trial Design and Analysis -- Exact Inference for Adaptive Group Sequential Designs -- A Novel Framework for Bayesian Response-Adaptive Randomization -- Sample Size Determination Under Non-proportional Hazards -- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting -- Part V: Biomarker-Driven Trial Design -- Clinical Trial Designs to Evaluate Predictive Biomarkers: What's Being Estimated? -- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies -- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy -- Part VI: Application of Novel Data Modality -- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneity with Deep Sequencing Data -- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials -- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development -- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors -- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework -- Part VII: Omics Data Analysis -- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study -- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.
Contained By:	Springer eBooks
標題:	Pharmaceutical industry - Congresses. - Statistical methods -
電子資源:	https://doi.org/10.1007/978-3-319-67386-8
ISBN:	9783319673868

Pharmaceutical statistics = MBSW 39, Muncie, Indiana, USA, May 16-18, 2016 /
Pharmaceutical statisticsMBSW 39, Muncie, Indiana, USA, May 16-18, 2016 /[electronic resource] :edited by Ray Liu, Yi Tsong. - Cham :Springer International Publishing :2019. - xi, 337 p. :ill., digital ;24 cm. - Springer proceedings in mathematics & statistics,v.2182194-1009 ;. - Springer proceedings in mathematics & statistics ;v.218..

Part I: Specification and Sampling Acceptance Tests -- Statistical Considerations in Setting Quality Specification Limits Using Quality Data -- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes -- Part II: Analytical Biosimilar and Process Validation -- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment -- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study -- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment -- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules -- Part III: Continuous Process -- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach -- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle -- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach -- Part IV: Clinical Trial Design and Analysis -- Exact Inference for Adaptive Group Sequential Designs -- A Novel Framework for Bayesian Response-Adaptive Randomization -- Sample Size Determination Under Non-proportional Hazards -- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting -- Part V: Biomarker-Driven Trial Design -- Clinical Trial Designs to Evaluate Predictive Biomarkers: What's Being Estimated? -- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies -- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy -- Part VI: Application of Novel Data Modality -- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneity with Deep Sequencing Data -- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials -- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development -- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors -- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework -- Part VII: Omics Data Analysis -- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study -- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.

This book presents the proceedings of the 39th annual Midwest Biopharmaceutical Statistics Workshop (MBSW), held in Muncie, Indiana on May 16-18, 2016. It consists of selected peer- reviewed and revised papers on topics ranging from statistical applications in drug discovery and CMC to biomarkers, clinical trials, and statistical programming. All contributions feature original research, and together they cover the full spectrum of pharmaceutical R&D - with a special focus on emergent topics such as biosimilarity, bioequivalence, clinical trial design, and subgroup identification. Founded in 1978, the MBSW has provided a forum for statisticians to share knowledge, research, and applications on key statistical topics in pharmaceutical R&D for almost forty years, with the 2016 conference theme being "The Power and 3 I's of Statistics: Innovation, Impact and Integrity." The papers gathered here will be of interest to all researchers whose work involves the quantitative aspects of pharmaceutical research and development, including pharmaceutical statisticians who want to keep up-to-date with the latest trends, as well as academic statistics researchers looking for areas of application.

ISBN: 9783319673868

Standard No.: 10.1007/978-3-319-67386-8doiSubjects--Topical Terms:

3412536
Pharmaceutical industry
--Statistical methods--Congresses.

LC Class. No.: RS57 / .M53 2016

Dewey Class. No.: 615

Pharmaceutical statistics = MBSW 39, Muncie, Indiana, USA, May 16-18, 2016 /
LDR:04991nmm a2200349 a 4500 001 2192321
003 DE-He213
005 20190618161315.0
006 m d
007 cr nn 008maaau
008 200506s2019 gw s 0 eng d
020 $a 9783319673868 $q (electronic bk.)
020 $a 9783319673851 $q (paper)
024 7 $a 10.1007/978-3-319-67386-8 $2 doi
035 $a 978-3-319-67386-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RS57 $b .M53 2016
072 7 $a PBT $2 bicssc
072 7 $a MED090000 $2 bisacsh
072 7 $a PBT $2 thema
072 7 $a MBNS $2 thema
082 0 4 $a 615 $2 23
090 $a RS57 $b .M629 2016
111 2 $a Midwest Biopharmaceutical Statistics Workshop $n (39th : $d 2016 : Muncie, Ind.) $3 3412532
245 1 0 $a Pharmaceutical statistics $h [electronic resource] : $b MBSW 39, Muncie, Indiana, USA, May 16-18, 2016 / $c edited by Ray Liu, Yi Tsong.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a xi, 337 p. : $b ill., digital ; $c 24 cm.
490 1 $a Springer proceedings in mathematics & statistics, $x 2194-1009 ; $v v.218
505 0 $a Part I: Specification and Sampling Acceptance Tests -- Statistical Considerations in Setting Quality Specification Limits Using Quality Data -- Counting Test and Parametric Two One-Sided Tolerance Interval Test for Content Uniformity Using Large Sample Sizes -- Part II: Analytical Biosimilar and Process Validation -- Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment -- A Probability Based Equivalence Test of NIR Versus HPLC Analytical Methods in a Continuous Manufacturing Process Validation Study -- A Further Look at the Current Equivalence Test for Analytical Similarity Assessment -- Shiny Tools for Sample Size Calculation in Process Performance Qualification of Large Molecules -- Part III: Continuous Process -- Risk Evaluation of Registered Specifications and Internal Release Limits Using a Bayesian Approach -- Development of Statistical Computational Tools Through Pharmaceutical Drug Development and Manufacturing Life Cycle -- Application of Advanced Statistical Tools to Achieve Continuous Analytical Verification: A Risk Assessment Case of the Impact of Analytical Method Performance on Process Performance Using a Bayesian Approach -- Part IV: Clinical Trial Design and Analysis -- Exact Inference for Adaptive Group Sequential Designs -- A Novel Framework for Bayesian Response-Adaptive Randomization -- Sample Size Determination Under Non-proportional Hazards -- Adaptive Three-Stage Clinical Trial Design for a Binary Endpoint in the Rare Disease Setting -- Part V: Biomarker-Driven Trial Design -- Clinical Trial Designs to Evaluate Predictive Biomarkers: What's Being Estimated? -- Biomarker Enrichment Design Considerations in Oncology Single Arm Studies -- Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy -- Part VI: Application of Novel Data Modality -- Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneity with Deep Sequencing Data -- Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials -- Project Data Sphere and the Applications of Historical Patient Level Clinical Trial Data in Oncology Drug Development -- Novel Test for the Equality of Continuous Curves with Homoscedastic or Heteroscedastic Measurement Errors -- Quality Control Metrics for Extraction-Free Targeted RNA-Seq Under a Compositional Framework -- Part VII: Omics Data Analysis -- Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study -- A Simulation Study Comparing SNP Based Prediction Models of Drug Response.
520 $a This book presents the proceedings of the 39th annual Midwest Biopharmaceutical Statistics Workshop (MBSW), held in Muncie, Indiana on May 16-18, 2016. It consists of selected peer- reviewed and revised papers on topics ranging from statistical applications in drug discovery and CMC to biomarkers, clinical trials, and statistical programming. All contributions feature original research, and together they cover the full spectrum of pharmaceutical R&D - with a special focus on emergent topics such as biosimilarity, bioequivalence, clinical trial design, and subgroup identification. Founded in 1978, the MBSW has provided a forum for statisticians to share knowledge, research, and applications on key statistical topics in pharmaceutical R&D for almost forty years, with the 2016 conference theme being "The Power and 3 I's of Statistics: Innovation, Impact and Integrity." The papers gathered here will be of interest to all researchers whose work involves the quantitative aspects of pharmaceutical research and development, including pharmaceutical statisticians who want to keep up-to-date with the latest trends, as well as academic statistics researchers looking for areas of application.
650 0 $a Pharmaceutical industry $x Statistical methods $v Congresses. $3 3412536
650 0 $a Pharmacy $x Statistical methods $v Congresses. $3 3412537
650 1 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 891086
650 2 4 $a Biostatistics. $3 1002712
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Statistical Theory and Methods. $3 891074
700 1 $a Liu, Ray. $3 3412533
700 1 $a Tsong, Yi. $3 3412534
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Springer proceedings in mathematics & statistics ; $v v.218. $3 3412535
856 4 0 $u https://doi.org/10.1007/978-3-319-67386-8
950 $a Mathematics and Statistics (Springer-11649)